Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

In vivo metabole profilering van CLL (chronische lymfatische leukemie)

17 november 2026 bijgewerkt door: University of Wisconsin, Madison

Metabole profilering van leukemische cellen door middel van isotopentracering bij patiënten met CLL

Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology.

A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators "simplistic" understanding of metabolic reprogramming in cancer. Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies, fuel preferences, and underlying mechanisms in the specific physiological context. However, today's data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies. Here, the investigators propose a "top-down" approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities.

Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient. Incorporated stable, non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis. Using this method, investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner.

Studie Overzicht

Toestand

Werving

Studietype

Observationeel

Inschrijving (Geschat)

16

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Wisconsin
      • Madison, Wisconsin, Verenigde Staten, 53705
        • Werving
        • University of Wisconsin

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

To meet the study aims sixteen (16) adult participants will be enrolled: four (4) healthy volunteers defined as people without a history of cancer, 8 patients with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0, and 4 patients with high disease burden CLL defined as having extensive infiltration of the bone marrow.

Beschrijving

Inclusion Criteria:

Group A

  • Adult (18 years of age or older)
  • No previous history of cancer
  • Routine history of normal blood counts and vital signs
  • Documented Informed Consent

Group B

  • Adult (18 years of age or older)
  • Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.)
  • Treatment naïve
  • Documented Informed Consent

Group C

  • Adult (18 years of age or older)
  • Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia
  • Treatment naïve
  • Able/willing to have bone marrow aspiration
  • Documented Informed Consent

Exclusion Criteria:

For all participants

  • Prisoners
  • Psychiatric inpatients or people who are institutionalized
  • Minor (Less than 18 years of age)
  • History of diabetes
  • Cannot be on antihyperglycemic therapy
  • Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc.
  • Females of child bearing potential
  • Persons without decision-making capacity
  • Person who cannot read/write English
  • Not meeting inclusion criteria defined above

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: CASE_CONTROL
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Group A: Healthy volunteers

Healthy volunteers are defined as people without a history of cancer

[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden

Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.

6mg/kg of body weight of [13C5]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Group B subset-2: Treatment naïve CLL patients with low disease burden

Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.

[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Group C:Treatment naïve CLL patients with high systemic disease burden

Treatment naïve CLL patients with high systemic disease burden

[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis
Tijdsspanne: up to 2 hours (± 5 minutes)

It will reveal how CLL cells utilize glucose compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting.

up to 2 hours (± 5 minutes)
Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysis
Tijdsspanne: up to 2 hours (± 5 minutes)

It will reveal how CLL cells utilize glutamine compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting.

up to 2 hours (± 5 minutes)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Validate ex vivo labeling model to assay metabolism
Tijdsspanne: 10 minutes

Study team seek to develop a more cost-effective ex vivo model to assay metabolism under conditions closest to the physiological setting in a small amount of blood. In addition, this model will allow numerous pharmacologic interventions and may serve as a personalized ex vivo drug screening assay.

Participants will be on overnight fasting. Cells and plasma will be separated from 5 ml of pre infused blood. Cell suspensions will be incubated at 37°C for 2hrs and intracellular and extracellular metabolites will be extracted separately for LCMS analysis.

10 minutes

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 juni 2022

Primaire voltooiing (Geschat)

1 april 2027

Studie voltooiing (Geschat)

1 april 2027

Studieregistratiedata

Eerst ingediend

25 februari 2021

Eerst ingediend dat voldeed aan de QC-criteria

4 maart 2021

Eerst geplaatst (Werkelijk)

8 maart 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • UW20062
  • A534260 (Andere identificatie: UW Madison)
  • SMPH/MEDICINE/HEM-ONC (Andere identificatie: UW Madison)
  • MSN240796 (Ander subsidie-/financieringsnummer: WISCONSIN ALUMNI RESEARCH FOUNDATION)
  • 2020-1008 (Andere identificatie: HSIRB UW Madison)
  • Protocol Version 10/19/2022 (Andere identificatie: UW Madison)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren